🇪🇺 ASP0456 in European Union

EMA authorised ASP0456 on 26 November 2012

Marketing authorisation

EMA — authorised 26 November 2012

  • Application: EMEA/H/C/002490
  • Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
  • Local brand name: Constella
  • Indication: Constella is indicated for the symptomatic treatment of moderate to severe irritable-bowel syndrome with constipation (IBS-C) in adults.
  • Status: approved

Read official source →

ASP0456 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is ASP0456 approved in European Union?

Yes. EMA authorised it on 26 November 2012.

Who is the marketing authorisation holder for ASP0456 in European Union?

AbbVie Deutschland GmbH & Co. KG holds the EU marketing authorisation.